Anti-TGF beta Receptor I (phospho S165) antibody (ab112095)
Key features and details
- Rabbit polyclonal to TGF beta Receptor I (phospho S165)
- Suitable for: ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-TGF beta Receptor I (phospho S165) antibody
See all TGF beta Receptor I primary antibodies -
Description
Rabbit polyclonal to TGF beta Receptor I (phospho S165) -
Host species
Rabbit -
Specificity
ab112095 detects endogenous levels of TGF beta Receptor I only when phosphorylated at serine 165. -
Tested applications
Suitable for: ICC/IFmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat
-
Immunogen
-
Positive control
- HeLa cells.
-
General notes
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.88% Sodium chloride, 49% PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab112095 is affinity-purified from rabbit antiserum by affinity-chromatography using an epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab112095 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| ICC/IF | 1/100 - 1/500. |
Target
-
Function
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta. -
Tissue specificity
Found in all tissues examined, most abundant in placenta and least abundant in brain and heart. -
Involvement in disease
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. -
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Contains 1 GS domain.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 7046 Human
- Entrez Gene: 21812 Mouse
- Entrez Gene: 29591 Rat
- Omim: 190181 Human
- SwissProt: P36897 Human
- SwissProt: Q64729 Mouse
- SwissProt: P80204 Rat
- Unigene: 494622 Human
see all -
Alternative names
- AAT 5 antibody
- AAT5 antibody
- Activin A receptor type II like kinase 53kDa antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-TGF beta Receptor I (phospho S165) antibody (ab112095)ab112095, at a 1/100 dilution, staining TGF beta Receptor I in HeLa cells by Immunofluorescence, in the absence (left) and presence (right) of the phosphopeptide.
Protocols
Datasheets and documents
References (8)
ab112095 has been referenced in 8 publications.
- Lou LL et al. (+)-Isobicyclogermacrenal and spathulenol from Aristolochia yunnanensis alleviate cardiac fibrosis by inhibiting transforming growth factor ß/small mother against decapentaplegic signaling pathway. Phytother Res 33:214-223 (2019). PubMed: 30375049
- Wojciech S et al. The orphan GPR50 receptor promotes constitutive TGFß receptor signaling and protects against cancer development. Nat Commun 9:1216 (2018). PubMed: 29572483
- Dalvi P et al. Hyperactive TGF-ß Signaling in Smooth Muscle Cells Exposed to HIV-protein(s) and Cocaine: Role in Pulmonary Vasculopathy. Sci Rep 7:10433 (2017). WB . PubMed: 28874783
- Liu Y et al. Decorin inhibits the proliferation of HepG2 cells by elevating the expression of transforming growth factor-ß receptor II. Exp Ther Med 12:2191-2195 (2016). WB ; Human . PubMed: 27698710
- Jin K et al. Hepatic Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines. Cancer Prev Res (Phila) 9:324-34 (2016). PubMed: 26851235
- Su CT et al. Latent transforming growth factor binding protein 4 regulates transforming growth factor beta receptor stability. Hum Mol Genet 24:4024-36 (2015). PubMed: 25882708
- Silva MT et al. Impaired structural and functional regeneration of skeletal muscles from ß2-adrenoceptor knockout mice. Acta Physiol (Oxf) 211:617-33 (2014). PubMed: 24938737
- Rudalska R et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138-46 (2014). PubMed: 25216638
